Results of a Second Year of Therapy with the 12-Month Histrelin Implant for the Treatment of Central Precocious Puberty

Background. Gonadotropin releasing hormone analogs (GnRHas) are standard of care for central precocious puberty (CPP). The histrelin subcutaneous implant is safe and effective in the treatment of CPP for one year. Objective. The study evaluates a second year of therapy in children with CPP who recei...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Rahhal, Samar, Clarke, William L., Kletter, Gad B., Lee, Peter A., Neely, E. Kirk, Reiter, Edward O., Saenger, Paul, Shulman, Dorothy, Silverman, Lawrence, Eugster, Erica A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Hindawi Publishing Corporation 2009
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2777002/
https://ncbi.nlm.nih.gov/pubmed/19956699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2009/812517
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi